7,574.89

-145.50

-1.88%

51,838.42

-504.14

-0.96%

25,366.65

-818.08

-3.12%

2,801.29

-57.92

-2.03%

4.9390

-0.0500

-1.00%

21.01

+3.81

+22.10%

3,898.30

-133.10

-3.30%

77,064.77

-3,733.72

-4.62%

Crude Oil Dec 26

104.90

+2.90

+2.84%

US Private Equity

10,932.82

-7.68

-0.07%

NasdaqCM - Nasdaq Real Time Price USD

IN8bio, Inc. (INAB)

0.9199 -0.0602 (-6.14%)

As of 1:34:26 PM EDT. Market Open.

Loading Chart for INAB

Chart Range Bar

Interval:

In partnership with ChartIQ

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio to Present at Sidoti Small-Cap Virtual Conference

IN8bio to Present at Sidoti Small-Cap Virtual Conference

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

Mobilize your Website

View Site in Mobile | Classic

Share by: